Zobrazeno 1 - 10
of 122
pro vyhledávání: '"G Derigs"'
Autor:
Veronika Brixner, Gesine Bug, Petra Pohler, Doris Krämer, Bernd Metzner, Andreas Voss, Jochen Casper, Ulrich Ritter, Stefan Klein, Nael Alakel, Rudolf Peceny, Hans G. Derigs, Frank Stegelmann, Martin Wolf, Hubert Schrezenmeier, Thomas Thiele, Erhard Seifried, Hans-Hermann Kapels, Andrea Döscher, Eduard K. Petershofen, Thomas H. Müller, Axel Seltsam
Publikováno v:
Haematologica, Vol 106, Iss 4 (2021)
Pathogen reduction (PR) technologies for blood components have been established to reduce the residual risk of known and emerging infectious agents. THERAFLEX UVPlatelets, a novel UVC light-based PR technology for platelet concentrates, works without
Externí odkaz:
https://doaj.org/article/e2852c63bc044be2b5740649a1c09838
Autor:
Ralf-Dieter Hofheinz, Sandro Anchisi, Birgit Grünberger, Hans G. Derigs, Mark-Oliver Zahn, Christine Geffriaud-Ricouard, Max Gueldner, Christine Windemuth-Kieselbach, Stefanie Pederiva, Pierre Bohanes, Felicitas Scholten, Gudrun Piringer, Josef Thaler, Roger von Moos
Publikováno v:
Cancers; Volume 14; Issue 14; Pages: 3522
Aflibercept plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer after the failure of oxaliplatin-containing therapy. QoLiTrap prospectively evaluated the quality of life (QoL) and effectiveness of this regimen in
Autor:
M-O. Zahn, Josef Thaler, Christine Windemuth-Kieselbach, Gudrun Piringer, Sandro Anchisi, F. Scholten, R.D. Hofheinz, R. von Moos, B. Grünberger, Pierre Oliver Bohanes, Stefanie Pederiva, H. Kröning, H.-G. Derigs
Publikováno v:
Annals of Oncology. 32:S574-S575
Publikováno v:
Mediators of Inflammation, Vol 7, Iss 3, Pp 195-199 (1998)
The stimulation of granulocyte macrophage-colony stimulating factor (GM-CSF) by interleukin-1 (IL-1) has been shown to be counteracted in different mesenchymal cell systems by cyclic adenosine monophosphate (cAMP) agonists. The aim of this study was
Externí odkaz:
https://doaj.org/article/3f9f8fd5179f49ae9a44c7318497df52
Autor:
Stefan Klein, Rudolf Peceny, Doris Krämer, Andreas Voss, Nael Alakel, Jochen Casper, Bernd Metzner, Gesine Bug, Hans-Hermann Kapels, Hans G Derigs, Eduard K. Petershofen, Petra Pohler, Martin Wolf, Hubert Schrezenmeier, Thomas Müller, Erhard Seifried, Andrea Döscher, Axel Seltsam, Thomas Thiele, Veronika Brixner, Frank Stegelmann, Ulrich Ritter
Publikováno v:
Haematologica
Pathogen reduction (PR) technologies for blood components have been established to reduce the residual risk of known and emerging infectious agents. THERAFLEX UVPlatelets, a novel UVC light-based PR technology for platelet concentrates, works without
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Dirk Behringer, S. Bröckling, Lothar Müller, J-C. Moulin, S-E. Al-Batran, Claudia Pauligk, Arndt Vogel, T. Fietz, Anna Saborowski, N. Moosmann, Christoph B. Westphalen, T.O. Götze, Jochem Potenberg, Manfred P. Lutz, M.K. Schuler, E. Späth-Schwalbe, J. Chater, Frank Hartmann, B. Zäpf, H.-G. Derigs
Publikováno v:
Annals of Oncology. 32:S1255
Autor:
Kathleen M Mullane, Vicki A Morrison, Luis H Camacho, Ann Arvin, Shelly A McNeil, Jessie Durrand, Bernadette Campbell, Shu-Chih Su, Ivan S F Chan, Janie Parrino, Susan S Kaplan, Zoran Popmihajlov, Paula W Annunziato, S Cerana, MO Dictar, P Bonvehi, JP Tregnaghi, L Fein, D Ashley, M Singh, T Hayes, G Playford, O Morrissey, J Thaler, T Kuehr, R Greil, M Pecherstorfer, L Duck, K Van Eygen, M Aoun, B De Prijck, FA Franke, CHE Barrios, AVA Mendes, SV Serrano, RF Garcia, F Moore, JFC Camargo, LA Pires, RS Alves, A Radinov, K Oreshkov, V Minchev, AI Hubenova, T Koynova, I Ivanov, B Rabotilova, PA Petrov, P Chilingirov, S Karanikolov, J Raynov, D Grimard, S McNeil, D Kumar, LM Larratt, K Weiss, R Delage, FJ Diaz-Mitoma, PO Cano, F Couture, P Carvajal, A Yepes, R Torres Ulloa, P Fardella, C Caglevic, C Rojas, E Orellana, P Gonzalez, A Acevedo, KM Galvez, ME Gonzalez, S Franco, JG Restrepo, CA Rojas, C Bonilla, LE Florez, AV Ospina, R Manneh, R Zorica, DV Vrdoljak, M Samarzija, L Petruzelka, J Vydra, J Mayer, D Cibula, J Prausova, G Paulson, M Ontaneda, K Palk, A Vahlberg, R Rooneem, F Galtier, D Postil, F Lucht, F Laine, O Launay, H Laurichesse, X Duval, OA Cornely, B Camerer, J Panse, M Zaiss, H-G Derigs, H Menzel, M Verbeek, V Georgoulias, D Mavroudis, A Anagnostopoulos, E Terpos, D Cortes, J Umanzor, S Bejarano, RW Galeano, RSM Wong, P Hui, P Pedrazzoli, L Ruggeri, F Aversa, A Bosi, G Gentile, A Rambaldi, A Contu, L Marei, A Abbadi, W Hayajneh, J Kattan, F Farhat, G Chahine, J Rutkauskiene, LJ Marfil Rivera, YA Lopez Chuken, H Franco Villarreal, J Lopez Hernandez, H Blacklock, RI Lopez, R Alvarez, AM Gomez, TS Quintana, MDC Moreno Larrea, SJ Zorrilla, E Alarcon, FCA Samanez, PB Caguioa, BJ Tiangco, EM Mora, RD Betancourt-Garcia, D Hallman-Navarro, LJ Feliciano-Lopez, HA Velez-Cortes, F Cabanillas, DE Ganea, TE Ciuleanu, DG Ghizdavescu, L Miron, CL Cebotaru, CI Cainap, R Anghel, MV Dvorkin, OA Gladkov, NV Fadeeva, AA Kuzmin, ON Lipatov, II Zbarskaya, FS Akhmetzyanov, IV Litvinov, BV Afanasyev, M Cherenkova, D Lioznov, IA Lisukov, YA Smirnova, S Kolomietz, H Halawani, YT Goh, L Drgona, J Chudej, M Matejkova, M Reckova, BL Rapoport, WM Szpak, DR Malan, N Jonas, CW Jung, DG Lee, SS Yoon, J Lopez Jimenez, I Duran Martinez, JF Rodriguez Moreno, C Solano Vercet, R de la Camara, M Batlle Massana, S-P Yeh, C-Y Chen, H-H Chou, C-M Tsai, C-H Chiu, N Siritanaratkul, L Norasetthada, V Sriuranpong, K Seetalarom, H Akan, F Dane, MA Ozcan, GH Ozsan, SF Kalayoglu Besisik, A Cagatay, S Yalcin, A Peniket, SR Mullan, KM Dakhil, K Sivarajan, JJ-G Suh, A Sehgal, F Marquez, EG Gomez, MR Mullane, WL Skinner, RJ Behrens, DR Trevarthe, MA Mazurczak, EA Lambiase, CA Vidal, SY Anac, GA Rodrigues, B Baltz, R Boccia, MS Wertheim, CS Holladay, D Zenk, W Fusselman, JL Wade III, AJ Jaslowsk, J Keegan, MO Robinson, RS Go, J Farnen, B Amin, D Jurgens, GF Risi, PG Beatty, T Naqvi, S Parshad, VL Hansen, M Ahmed, PD Steen, S Badarinath, A Dekker, MA Scouros, DE Young, W Graydon Harker, SD Kendall, ML Citron, S Chedid, JG Posada, MK Gupta, S Rafiyath, J Buechler-Price, S Sreenivasappa, CH Chay, JM Burke, SE Young, A Mahmood, JW Kugler, G Gerstner, J Fuloria, ND Belman, R Geller, J Nieva, BP Whittenberger, BMY Wong, TP Cescon, G Abesada-Terk, MJ Guarino, A Zweibach, EN Ibrahim, G Takahashi, MA Garrison, RB Mowat, BS Choi, IA Oliff, J Singh, KA Guter, K Ayrons, KM Rowland, SJ Noga, SB Rao, A Columbie, MT Nualart, GR Cecchi, LT Campos, M Mohebtash, MR Flores, R Rothstein-Rubin, BM O'Connor, G Soori, M Knapp, FG Miranda, BW Goodgame, M Kassem, R Belani, S Sharma, T Ortiz, HL Sonneborn, AB Markowitz, D Wilbur, E Meiri, VS Koo, HS Jhangiani, L Wong, S Sanani, SJ Lawrence, CM Jones, C Murray, C Papageorgiou, JS Gurtler, JL Ascensao, ML Venigalla, M D'Andrea, C De Las Casas, DJ Haile, FU Qazi, JL Santander, MR Thomas, VP Rao, M Craig, RJ Garg, R Robles, RM Lyons, RK Stegemoller, S Goel, S Garg, P Lowry, C Lynch, B Lash, T Repka, J Baker, BS Goueli, TC Campbell, DA Van Echo, YJ Lee, EA Reyes, FM Senecal, G Donnelly, P Byeff, R Weiss, T Reid, E Roeland, A Goel, DM Prow, DS Brandt, HG Kaplan, JE Payne, MG Boeckh, PJ Rosen, RR Mena, R Khan, RF Betts, SA Sharp, VA Morrison, D Fitz-Patrick, J Congdon, N Erickson, R Abbasi, S Henderson, A Mehdi, EJ Wos, E Rehmus, L Beltzer, RA Tamayo, T Mahmood, AC Reboli, A Moore, JM Brown, J Cruz, DP Quick, JL Potz, KW Kotz, M Hutchins, NM Chowhan, YD Devabhaktuni, P Braly, RA Berenguer, SC Shambaugh, TJ O'Rourke, WA Conkright, CF Winkler, FEK Addo, JP Duic, KP High, ME Kutner, R Collins, DR Carrizosa, DJ Perry, E Kailath, N Rosen, R Sotolongo, S Shoham, T Chen
Summary Background Patients who are immunocompromised because of malignancy have an increased risk of herpes zoster and herpes zoster-related complications. We aimed to investigate the efficacy and safety of an inactivated varicella zoster virus (VZV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9512b960de076ec44f04d635a16f9143
http://hdl.handle.net/11573/1331005
http://hdl.handle.net/11573/1331005
Publikováno v:
Annals of Oncology. 30:v224-v225
Background The anti-angiogenic fusion protein AFL targets VEGF-A, VEGF-B and PlGF. It is approved in combination with FOLFIRI for treatment of mCRC that is resistant to or has progressed after oxaliplatin-containing therapy. Methods QoLiTrap is an on
Publikováno v:
Annals of Oncology. 30:iv118